Overview
The National Cancer Institute (NCI) launched the PDX (patient-derived xenografts) Development and Trial Centers Research Network (PDXNet) in September 2017 to accelerate translational research using PDX datasets. The NCI renewed the program in 2023 with a focus of generating new LOIs.

The PDXNet comprises six PDX Development and Trial Centers (PDTCs) and the PDX Data Commons and Coordinating Center (PDCCC). Two PDTCs added focus exclusively on developing minority PDXs. Although nearly all the PDTC contibute to teh collection of Minority PDXx. The PDTCs and the PDCCC work together to test and advance multi-agent cancer treatments from PDX studies to human clinical trials.

PDXNet is an inclusive consortium that welcomes collaborations, in part through funded supplements. Please get in touch with us to discuss how we can work together to advance new cancer treatments.

Please visit the PDXNet portal to review resources generated by the PDXNet community.

 

PDXNet 2024 Annual Meeting at AACR

Funding provided by the NIH to the PDXNet Data Commons and Coordination Center (NCI U24-CA224067), to the PDX Development and Trial Centers (NCI U54-CA224083, NCI U54-CA224070, NCI U54-CA224065, NCI U54-CA224076, NCI U54-CA233223, and NCI U54-CA233306) and to the National Cancer Institute Cancer Genomics Cloud (HHSN261201400008C and HHSN261201500003I).